AL-ADTRAN
23.5.2024 14:01:26 CEST | Business Wire | Press release
Adtran today announced that this month marks the 75th anniversary of Oscilloquartz. Founded in 1949, Oscilloquartz has evolved into a global leader in PNT network timing technology, setting numerous industry benchmarks throughout its history. The company offers precision synchronization solutions that empower customers to overcome timing challenges in sectors from telecoms to critical defense infrastructure. Over the years, Oscilloquartz has consistently led the way with groundbreaking achievements, such as introducing the industry’s first optical cesium atomic clocks with optical pumping technology, which provide unparalleled accuracy and reliability. This month also commemorates 10 years since Oscilloquartz was acquired by ADVA, now part of Adtran, helping it expand its portfolio of cost-effective timing technologies and establish the leading assured PNT platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523252321/en/
Adtran’s Oscilloquartz timing technology is playing a key role in helping organizations strengthen critical network infrastructure. (Photo: Business Wire)
“Celebrating 75 years of Oscilloquartz, alongside a decade since our integration into the Adtran family, represents a remarkable achievement. The dual anniversary highlights our enduring commitment to timing innovation and quality. Throughout these decades, we’ve navigated the evolving landscape from frequency solutions for legacy SONET/SDH to highly accurate frequency and time solutions for packet-based networks. Our dedication has enabled us to offer scalable technology that ensures robust timing, with or without satellite signals,” said Gil Biran, GM of Oscilloquartz, Adtran. “From pioneering the integration of synchronization delivery and assurance to bringing timing closer to end applications through our compact, low-power devices, including our latest family of OSAinside™ products, our portfolio has consistently addressed our customers’ key challenges. More recently, the introduction of the first commercial optical cesium atomic clocks was another major leap, significantly enhancing the precision and stability of network timing while substantially extending lifespan.”
Since its inception, Oscilloquartz has led the field in network synchronization, setting standards with the industry’s first commercial magnetic cesium atomic clock in 1966 and spearheading telecoms timing solutions in 1978. In 1982, it transformed the market by introducing the first high-performance quartz oscillators and resonators, which played a key role in developing the European Digital Cesium Standard in 1988. After its acquisition in 2014, Oscilloquartz expanded its global presence, with leading service providers adopting its products. It also provided customized solutions across metrology, finance and national defense sectors. Its leadership in cesium clock technology won support for its R&D initiatives from the European Space Agency. Continuing its legacy of innovation, Oscilloquartz recently enhanced the resiliency of GPS/GNSS systems with its Iridium®-based Satellite Time and Location (STL) technology solutions, leveraging low-Earth orbit satellite signals for more reliable, secure synchronization even in challenging environments.
“This historic anniversary is a moment to appreciate Oscilloquartz’s incredible journey, from its initial project at the astronomical observatory in Neuchâtel 70 years ago to the forefront of timing technology today,” commented Christoph Glingener, CTO of Adtran. “Over the last decade, the integration with ADVA and then Adtran has enriched Oscilloquartz’s offerings through the combined expertise of our teams. This era saw the debut of compact and cost-effective Oscilloquartz synchronization devices, delivering unmatched precision at the network edge. Its core grandmasters set new industry benchmarks with their 10GbE support and hardware timestamping. Together with Oscilloquartz’s optical atomic cesium clocks, they create a SePRTC+, guaranteeing accurate, reliable timing even during GNSS disruptions for up to 100 days. This combination of the industry’s most scalable family of grandmasters based on zero-trust architecture, coupled with optical pumping technology, sets Oscilloquartz apart today. As part of the Adtran family, Oscilloquartz will continue its legacy of excellence, keeping customers at the forefront of synchronization technology.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523252321/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
